TW200605906A - Remedy for thrombopenia - Google Patents

Remedy for thrombopenia

Info

Publication number
TW200605906A
TW200605906A TW094113923A TW94113923A TW200605906A TW 200605906 A TW200605906 A TW 200605906A TW 094113923 A TW094113923 A TW 094113923A TW 94113923 A TW94113923 A TW 94113923A TW 200605906 A TW200605906 A TW 200605906A
Authority
TW
Taiwan
Prior art keywords
antihuman
activity
antibody
vb22b
found out
Prior art date
Application number
TW094113923A
Other languages
English (en)
Chinese (zh)
Inventor
Masayuki Tsuchiya
Tetsuro Orita
Yoshihiro Matsumoto
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of TW200605906A publication Critical patent/TW200605906A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW094113923A 2004-05-11 2005-04-29 Remedy for thrombopenia TW200605906A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004141618 2004-05-11

Publications (1)

Publication Number Publication Date
TW200605906A true TW200605906A (en) 2006-02-16

Family

ID=35320039

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094113923A TW200605906A (en) 2004-05-11 2005-04-29 Remedy for thrombopenia

Country Status (3)

Country Link
JP (1) JPWO2005107784A1 (fr)
TW (1) TW200605906A (fr)
WO (1) WO2005107784A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
JP4794301B2 (ja) 2003-06-11 2011-10-19 中外製薬株式会社 抗体の製造方法
JP5057967B2 (ja) 2005-03-31 2012-10-24 中外製薬株式会社 ｓｃ（Ｆｖ）２構造異性体
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
KR101367544B1 (ko) 2005-06-10 2014-02-26 추가이 세이야쿠 가부시키가이샤 메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용
WO2006132352A1 (fr) * 2005-06-10 2006-12-14 Chugai Seiyaku Kabushiki Kaisha Composition pharmaceutique contenant sc(fv)2
CA2611726C (fr) * 2005-06-10 2017-07-11 Chugai Seiyaku Kabushiki Kaisha Composition pharmaceutique contenant sc(fv)2
EP2009101B1 (fr) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Procede de modification d'anticorps pour purifier un anticorps bispecifique
WO2007145227A1 (fr) 2006-06-14 2007-12-21 Chugai Seiyaku Kabushiki Kaisha Promoteur de la prolifération des cellules souches hématopoïétiques
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
BR112015029280A2 (pt) * 2013-05-24 2017-07-25 Kunming Shenghuo Pharmaceutical Group Co Ltd dencichine para a utilização no tratamento da trombocitopenia e para a utilização na fabricação de um medicamento
ES2881306T3 (es) 2013-09-27 2021-11-29 Chugai Pharmaceutical Co Ltd Método para la producción de heteromultímeros de polipéptidos
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09289892A (ja) * 1996-04-25 1997-11-11 Yamanouchi Pharmaceut Co Ltd ｃ−ＭＰＬリガンドアゴニスト抗体
US6342220B1 (en) * 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
AU1091802A (en) * 2000-10-20 2002-04-29 Chugai Pharmaceutical Co Ltd Degraded agonist antibody
WO2002033072A1 (fr) * 2000-10-20 2002-04-25 Chugai Seiyaku Kabushiki Kaisha Anticorps degrade, agoniste de tpo
TW200530266A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Method of reinforcing antibody activity
TW200530269A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies

Also Published As

Publication number Publication date
WO2005107784A1 (fr) 2005-11-17
JPWO2005107784A1 (ja) 2008-03-21

Similar Documents

Publication Publication Date Title
TW200605906A (en) Remedy for thrombopenia
NO20063224L (no) Anti-MPL-antistoff
BRPI0720462A2 (pt) Compactos abrasivos com maquinabilidade aperfeiçoada
WO2007024535A3 (fr) Anticorps antagonistes contre gdf-8 et utilisations pour le traitement de als et d'autres troubles associes a gdf-8
IL172321A (en) Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
IL244803B (en) Human anti-beta antibodies and their use
GEP20166454B (en) Sclerostin binding agents
WO2007008712A8 (fr) Anticorps anti-alpha v beta 6 et leurs utilisations
SG10201407388XA (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
EP2143795A3 (fr) Anticorps monoclonal anti-CD20
MY145073A (en) Anti-glypican 3 antibody
ATE518952T1 (de) Bispezifischer antikörper als ersatz für factor viii
EA201070596A1 (ru) Гуманизированные антитела против tl1a
SG146696A1 (en) Humanized antibodies against vascular endothelial growth factor
MY143215A (en) Multifocal lenses for pre-presbyopic individuals
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
DK1755634T3 (da) Oligopeptider til formindskelse af forhöjet blodurinstofkoncentration
CY2022028I2 (el) Εξανθρωπισμενα αντισωματα αντι-cd19 και οι χρησεις τους στην θεραπεια ογκων, μεταμοσχευσης και ασθενειων αυτο-ανοσιας
WO2009135861A3 (fr) Anticorps humanisés contre l'interféron-alpha humain
ITMI20031127A1 (it) Anticorpi anti-hgf-r e loro uso
IL171356A (en) Anti-interferon receptor antibody for treatment of inflammatory bowel disease
MXPA05008794A (es) Antigeno de glicoproteina sima135 expresado en celulas tumorales humanas metastasicas.
IL164011A0 (en) Antagonistic anti-hfas ligand human antibodies andfragments thereof
BRPI0410593A (pt) método para predição de distribuição de tamanho de grão a partir do formato de um corpo sedimentar
WO2006060753A3 (fr) Diagnostic et traitement de la maladie d'alzheimer